Inhafort

Formoterol fumarate dihydrate, the active ingredient in Inhafort, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation product for use via inhalation. It provides bronchodilation to help manage chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) in adult patients. The medication is formulated for delivery through a metered‑dose inhaler, allowing rapid onset of action and sustained airway opening over several hours.

GNH USA supplies Inhafort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inhafort, a long‑acting β2‑adrenergic agonist, is used to treat chronic obstructive airway diseases.

Asthma: improves lung function and reduces symptoms when used regularly as maintenance therapy. Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation to lessen breathlessness and improve exercise tolerance. Exercise‑induced bronchospasm: used as part of a combination regimen to prevent airway narrowing during physical activity.

Formoterol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient headache often resolving without treatment. - Throat irritation: dryness or irritation in the throat after inhalation. - Cough: occasional cough triggered by the inhaled powder. - Palpitations: sensation of rapid or irregular heartbeat. - Muscle cramps: occasional leg or calf cramps.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty requiring immediate care. - Cardiac arrhythmia: irregular heart rhythm that may need medical attention. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring emergency treatment.

When prescribing or using Inhafort, several precautions should be observed to ensure safety. - Assess cardiovascular status: evaluate for arrhythmias or ischemic heart disease before initiation. - Monitor asthma control: ensure patient has a rescue inhaler and review symptoms regularly. - Avoid use in known hypersensitivity: discontinue if allergic reactions occur. - Use with caution in severe COPD: consider risk of tachycardia and tremor. - Review concomitant beta‑blocker therapy: may diminish bronchodilator effect. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Formoterol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may antagonize the bronchodilator effect of formoterol and can precipitate bronchospasm, especially in patients with reactive airway disease. - Monoamine oxidase inhibitors (MAOIs): concurrent use can lead to severe hypertension due to additive sympathomimetic activity. - Diuretics: may enhance the risk of hypokalemia, which can exacerbate cardiac arrhythmias when combined with formoterol.

Moderate Interactions (Monitor Closely): - Theophylline: formoterol can increase theophylline plasma concentrations, so serum levels should be monitored and dosage adjusted if needed. - Corticosteroids: combined use may produce additive bronchodilation and increase the potential for systemic steroid effects; monitor for signs of over‑exposure. - Anticholinergic agents: when used together, there may be excessive tachycardia or palpitations; observe heart rate and adjust therapy as appropriate.